M28 Capital Management LP is an exempt reporting adviser based in Stamford, CT that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $113.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -56.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated -4.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- —Form ADV Item 5.F
- Gross assets of private funds
- $113.2 millionAll private fund types, Form ADV
- Hedge funds managed
- 13 private funds in total
- Employees
- —Form ADV Item 5.A
- Registration
- Exempt reporting adviserCRD 307490
- Latest Form ADV
- 04/22/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | -12.3% | +14.8% |
| Q1 2026 | -50.7% | -4.6% |
| Q4 2025 | +102.3% | +2.4% |
| Q3 2025 | +16.0% | +7.8% |
| Q2 2025 | -9.0% | +10.4% |
| Q1 2025 | -26.0% | -4.5% |
| Q4 2024 | +19.1% | +2.1% |
| Q3 2024 | +17.9% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 9 share positions ($36,042,654) reported by M28 Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Wave Life Sciences Inc.47.10%
- Invivyd Inc22.33%
- TG Therapeutics Inc13.67%
- Arrowhead Pharmaceuticals In6.69%
- Silence Therapeutics PLC3.07%
- Fractyl Health Inc2.80%
- Proqr Thrapeutics N V2.76%
- Rocket Pharmaceuticals Inc1.54%
- Curis Inc0.03%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Wave Life Sciences Inc. | $16,976,651 | 47.10% | 4,588,284 | New |
| Invivyd Inc | $8,046,902 | 22.33% | 9,248,250 | Unchanged |
| TG Therapeutics Inc | $4,928,386 | 13.67% | 88,354 | Unchanged |
| Arrowhead Pharmaceuticals In | $2,411,898 | 6.69% | 36,851 | Unchanged |
| Silence Therapeutics PLC | $1,106,149 | 3.07% | 101,203 | Unchanged |
| Fractyl Health Inc | $1,010,470 | 2.80% | 1,856,117 | Unchanged |
| Proqr Thrapeutics N V | $995,656 | 2.76% | 599,793 | Unchanged |
| Rocket Pharmaceuticals Inc | $554,591 | 1.54% | 210,871 | Unchanged |
| Curis Inc | $11,951 | 0.03% | 14,244 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 2 new positions, 2 sold out, 0 increased, 0 reduced and 7 unchanged.
Number of positions (a count, not dollars)
- New positions2
- Increased0
- Unchanged7
- Reduced0
- Sold out2
New positions
| Stock | Value | Shares |
|---|---|---|
| Wave Life Sciences Inc. | $16,976,651 | 4,588,284 |
| Curis Inc | $11,951 | 14,244 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Wave Life Sciences LTD | $26,657,930 | 4,588,284 |
| Curis Inc | $148,741 | 284,889 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Curis Inc | 13G amendment | 4.8% | 620,167 | Jan 23, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Jan 23, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (3)
As reported in the adviser's Form ADV filed Mar 29, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures